Fisher unit pursues RNA research

October 21, 2005

NH Business Review Staff,

A business unit of Fisher Scientific is teaming up with Alcon Incorporated to use RNA research to develop drugs that can be delivered through the eye.

Dharmacon, the Colorado based business unit of Fisher Biosciences, itself a unit of the Hampton-based corporation, specializes in making products that interfere with RNA, thus silencing disease-causing genes. This RNA interference (RNAi) enables it to target organisms that previously were not treatable by drugs.

Alcon, a German company with headquarters in Dallas, Texas, is known for its eye care products.

Financial terms of the multi-year deal were not disclosed. — NHBR STAFF REPORT

Categories: News

More news from NHBR:

Stand Alone Exterior Solar Panel System Installation, Renewable Green Energy Generation Concept.

New state law empowers homeowners with ‘balcony’ solar panels

With a new state law set to go into effect with the dawn of a new year in 2027, Granite Staters will be able to install so-called “balcony solar” panels for home use.

Building efficiency through partnerships

Marmon Utility President Ken Woo highlights how the company has been delivering electric infrastructure supports for 75 years

Shortening the line: from food insecurity to job security

Gather’s new culinary education program, Fresh Start, is a way to teach people with employment challenges the kitchen skills and life skills they need to have a career in the food service industry

Digital Balancing Scale Justice, Fairness In Modern Technology E

The hidden cost of AI: Who will train the next generation?

Artificial intelligence is transforming business at remarkable speed. Most discussions focus on productivity gains, cost savings or the jobs AI may eventually replace. Yet a more significant change is already underway — one that could reshape the future of nearly every profession.